Parkside Financial Bank & Trust Sells 66 Shares of Zoetis Inc. (NYSE:ZTS)

Parkside Financial Bank & Trust reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,873 shares of the company’s stock after selling 66 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Zoetis were worth $305,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Mizuho Securities USA LLC raised its holdings in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after purchasing an additional 4,829,815 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Zoetis by 296.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock worth $144,917,000 after purchasing an additional 665,331 shares during the last quarter. Nordea Investment Management AB raised its holdings in Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after purchasing an additional 572,511 shares during the last quarter. Holocene Advisors LP bought a new stake in Zoetis during the 3rd quarter worth about $110,809,000. Finally, Alecta Tjanstepension Omsesidigt bought a new stake in Zoetis during the 4th quarter worth about $83,835,000. 92.80% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Shares of ZTS opened at $167.58 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a 50 day simple moving average of $166.30 and a 200 day simple moving average of $177.38. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The firm has a market capitalization of $75.04 billion, a PE ratio of 30.64, a P/E/G ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ZTS shares. Morgan Stanley lowered their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Barclays upped their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.